THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH for THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R.2365/S.1064 - National Plan to End Parkinson's Act: a bill to create an advisory council comprising members of federal agencies that support research, care, and services for Parkinsons, plus patients, care partners, researchers, clinicians, and other non-federal experts to ensure efficient and effective coordination among all federal entities with responsibility for managing, treating, and curing Parkinsons disease. General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, environmental risks, and health access for underserved communities. Information related to prevalence particularly at CDC's National Neurological Conditions Surveillance System (NNCSS). S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care for people living with Parkinson's who experience OFF episodes and to allow researchers to gather more data to study the progression of the disease. Reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS). S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DREW CHARLES HATTER New | Legislative Assistant, US House of Representatives |
| TED THOMPSON | — |
| DUSTIN WATSON | — |
| MASON ZEAGLER | — |
Medicare/Medicaid MMM
Increasing prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining prior authorization processes. S.1544/H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023: a bill to establish separate payment requirements for diagnostic radiopharmaceuticals, including DaTscans, which can aid in confirming a Parkinson's diagnosis, under the Medicare prospective payment system for hospital outpatient department services. H.R.3432 - Telemental Health Care Access Act of 2023: a bill to permanently remove Medicare's originating site requirements for mental health services furnished via telehealth. Parkinson's non-motor symptoms encompass mental health conditions, including anxiety, depression, dementia, and other memory problems, and the majority of people living with Parkinson's in the United States are Medicare beneficiaries, many of whom will face undue burdens meeting the unnecessary in-person requirement for telemental health services after the delay of the requirement enforcement expires December 31, 2024. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MASON ZEAGLER | — |
Agriculture AGR
General education on risks of Parkinson's disease, including TCE, paraquat, air pollution, and other chemicals. Supporting creation of Neuroscience Center of Excellence at FDA. S.269, the Protect Americas Children from Toxic Pesticides Act (PACTPA). General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals. S.806, the Healthy H20 Act. Development of a legislative proposal to create a Neurodegenerative disease center of excellence program at NIEHS.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN MAY | — |
| TED THOMPSON | — |
Budget/Appropriations BUD
FY 2024 Appropriations bills including funding requests for Parkinson's research at: The Department of Defense within the FY 2024 Defense Appropriation bill (H.R.4365); The National Institute of Health and Centers for Disease Control and Prevention within the FY 2024 Labor, Health and Human Services, Education, and Related Agencies Appropriation bill (no bill introduced); The Food and Drug Administration within the FY 2024 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriation bill (H.R.4368); The Department of Veterans Affairs within the FY 2024 Military Construction, Veterans Affairs, and Related Agencies Appropriation bill (S.2127).
| Lobbyist | Covered position, as disclosed |
|---|---|
| DUSTIN WATSON | — |
| SALLIE JAMES WEART New | Senior Legislative Assistant, AmeriCorps (formerly Corporation for National and Community Service) |
Pharmacy PHA
Increasing prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining prior authorization processes. S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. H.R.830/S.1375 - Help Ensure Lower Patient Copays Act: a bill to require health insurance plans to apply certain payments made by, or on behalf of, a plan enrollee toward a plan's cost-sharing requirements. Specifically, plans must apply third-party payments, financial assistance, discounts, product vouchers, and other reductions in out-of-pocket expenses toward the requirements. Many Parkinson's patients rely on such third-party payments to afford medications to treat and manage their disease symptoms, and this legislation will ensure that all payments whether they come directly out of a pocket or with the help of copay assistance-counts toward out-of-pocket costs of patients. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MASON ZEAGLER | — |
Veterans VET
FY24 Military Construction, Veterans Affairs and Related Agencies Appropriations bill to support increased funding for the VA's Parkinson's Disease Research, Education and Clinical Center. General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease. Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN MAY | — |
| DUSTIN WATSON | — |
| SALLIE JAMES WEART New | Senior Legislative Assistant, AmeriCorps (formerly Corporation for National and Community Service) |
| MASON ZEAGLER | — |
Environment/Superfund ENV
General education regarding environmental triggers of neurological disease and Parkinson's along with support for more research. S.269, the Protect America's Children from Toxic Pesticides Act (PACTPA). More protective standards for particulate matter pollution.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN MAY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.